Related Experiment Video

Updated: Oct 18, 2025

An Orthotopic Murine Model of Human Prostate Cancer Metastasis
06:48

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

Published on: September 18, 2013

35.4K

Kartogenin Inhibits Prostate Cancer Cell Growth Through Smad2 Activation and Decreases Androgen Receptor Nuclear

Manabu Takai1, Kyojiro Kawakami2, Yasunori Fujita3

  • 1Department of Urology, Gifu University Graduate School of Medicine, Gifu, Japan.

Anticancer Research
|October 1, 2021
PubMed
Abstract

Insights

Kartogenin (KGN) shows promise in treating prostate cancer (PC) by inhibiting tumor growth and reactivating chemotherapy sensitivity in resistant cells. This differentiation-inducing compound targets key cancer progression pathways.

Area of Science:

  • Oncology
  • Cell Biology
  • Molecular Therapeutics

Background:

  • De-differentiation is a critical mechanism in cancer progression.
  • Prostate cancer (PC) cell de-differentiation contributes to tumor aggressiveness.
  • Identifying novel therapeutic agents targeting cancer cell differentiation is crucial.

Purpose of the Study:

  • To investigate the anti-tumor effects of kartogenin (KGN) on prostate cancer (PC) cells.
  • To evaluate KGN's impact on key molecular markers associated with PC progression.
  • To assess KGN's potential in overcoming treatment resistance in PC.

Main Methods:

  • Analysis of KGN's effect on androgen receptor (AR) nuclear localization and prostate-specific antigen (PSA) expression in PC cell lines.
  • Assessment of Smad2 activation in response to KGN treatment.
  • Evaluation of KGN's impact on the growth of various PC cell lines, including docetaxel-resistant variants.

Main Results:

  • KGN significantly inhibited the growth of AR-expressing PC cells (LNCaP, 22Rv1) but not AR-lacking cells (PC-3).
  • KGN reduced AR nuclear localization and PSA expression, indicating a potential reversal of de-differentiation.
  • KGN demonstrated efficacy against docetaxel-resistant PC cells (22Rv1DR) and restored sensitivity to docetaxel.

Conclusions:

  • Kartogenin exhibits significant anti-tumor activity in prostate cancer models.
  • KGN shows potential as a novel therapeutic agent for PC, particularly in cases of treatment failure or resistance.
  • Further investigation into KGN's mechanism and clinical application in PC is warranted.
Keywords:
Prostate cancerSmad2androgen receptorkartogenin

More Related Videos

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

13.5K
Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel06:44

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

13.6K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
8.0K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
8.4K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.2K
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
36.6K